Skip to main content
. Author manuscript; available in PMC: 2012 Mar 15.
Published in final edited form as: Clin Cancer Res. 2010 Dec 7;17(6):1351–1361. doi: 10.1158/1078-0432.CCR-10-1905

Figure 3.

Figure 3

Growth of BT474 xenograft tumors in athymic mice treated with estrogen supplementation (E2), or estrogen deprivation (ED) alone and with Lapatinib (L), trastuzumab (T), or their combination (L+T) in various doses and schedules. A. Growth of tumors in animals treated with ED plus short durations of (L+T) for 14 days (ED+L+T 14) and 42 days (ED+L+T 42) compared to control groups treated with E2, ED, ED+L, and ED+T. B. Growth of tumors treated with ED with full continuous (L+T), reduced dose therapy (1/2L+1/2T), or intermittent therapy (ED+L+T 14 on/off). For each group, the number of mice with complete tumor regression and the total number of mice are shown. Complete regression was defined as complete disappearance of the tumor for 3 consecutive weeks.